Inspirata Rebrands as Inspirata AI to Scale Oncology Data Automation

The platform utilizes a proprietary AI and natural language processing engine, supplemented by large language model integrations, to scan clinical documents as they are generated. By leveraging FHIR-based connectivity with pathology, laboratory, and radiology systems, the software identifies reportable cancer cases in real time. This automation aims to replace manual data entry, which has long burdened hospital cancer registry departments.

Satish Sanan, CEO of Inspirata AI, stated that the rebrand reflects two decades of underlying technical investment. The company claims the integration with ONCO’s registry workflow tools provides the market's only comprehensive solution for the entire cycle—from initial case identification to final data abstraction and analytics. Chief Technology Officer George Cernille noted that the firm avoids relying solely on LLMs, opting instead for a hybrid approach that uses proprietary algorithms for complex domain-specific tasks like SEER tumor rules.

With reported accuracy rates of 99%, the company positions its software as a tool to turn registry departments into strategic assets. By accelerating data visibility, healthcare providers can better support oncology service line growth, patient retention, and accreditation readiness. The system is currently deployed across various large-scale healthcare organizations in the United States, Canada, and Australia.